Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Ulf Christian Frølund"'
Autor:
Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Manuela Teodorescu, Kristina Buchardi Nielsen, Per Ishøy Nielsen, Per Trøllund Pedersen, Katrine Fladeland Iversen, Thomas Lund, Kirsten Grønbæk, Sigrun Thorsteinsdottir, Annette Vangsted, Agoston Gyula Szabo
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 316-324 (2024)
Abstract Lenalidomide maintenance (LM) has shown benefit in progression‐free survival (PFS) and overall survival (OS) in clinical trials. LM is the recommended standard of care in patients with newly diagnosed multiple myeloma (MM) after high‐dos
Externí odkaz:
https://doaj.org/article/9e33690602b2437da6963030afaaa7d7
Autor:
Christian Brieghel, Ólafur Davídsson, Klaus Rostgaard, Agoston Szabo, Ulf Christian Frølund, Henrik Hjalgrim, Carsten Niemann
Publikováno v:
HemaSphere, Vol 7, p e8949334 (2023)
Externí odkaz:
https://doaj.org/article/2abf0d82fa524e578c5a2fbb86f21d3e
Autor:
Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Todorescu, Kirsten Grønbæk, Kristina Buchardi Nielsen, Per Trøllund Pedersen, Katrine Fladeland Iversen, Sigrun Thorsteinsdottir, Annette Vangsted, Agoston Gyula Szabo
Publikováno v:
HemaSphere, Vol 7, p e4464961 (2023)
Externí odkaz:
https://doaj.org/article/286b612319774a56b1c626d94081090f
Autor:
Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called m
Externí odkaz:
https://doaj.org/article/5436faba1b7640768aa73dd91ad91f57
Autor:
Rikke Faebo Larsen, Mary Jarden, Lisbeth Rosenbek Minet, Ulf Christian Frølund, Sören Möller, Niels Abildgaard
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Multiple myeloma is a cancer in the bone marrow causing bone destruction. Patients experience various symptoms related to the disease and/or treatment, such as pain and fatigue, leading to poorer quality of life. The symptom burde
Externí odkaz:
https://doaj.org/article/b78fa6aa94164625b3e44e279859427b
Autor:
Rikke Faebo Larsen, Mary Jarden, Lisbeth Rosenbek Minet, Ulf Christian Frølund, Niels Abildgaard
Publikováno v:
Pilot and Feasibility Studies, Vol 5, Iss 1, Pp 1-11 (2019)
Abstract Background The study evaluated the feasibility and safety of the exercise intervention and physical test procedures of our ongoing randomized controlled trial, examining the effect of physical exercise in newly diagnosed patients with multip
Externí odkaz:
https://doaj.org/article/e5b75f3062f749d785e9f63e6422f958
Autor:
Henrik Gregersen, Trung Do, Ida Bruun Kristensen, Ulf Christian Frølund, Niels Frost Andersen, Lene Kongsgaard Nielsen, Christen Lykkegaard Andersen, Tobias Wirenfeldt Klausen, Annette Juul Vangsted, Niels Abildgaard
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-8 (2018)
Abstract Background The objective of this randomized placebo-controlled study was to investigate the efficacy and safety of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly diagnosed multip
Externí odkaz:
https://doaj.org/article/3f46901cd05842ae899969311f32b085
Autor:
Rasmus Sørrig, Tobias W Klausen, Morten Salomo, Annette J Vangsted, Ulf Christian Frølund, Kristian T Andersen, Anja Klostergaard, Carsten Helleberg, Robert S Pedersen, Per T Pedersen, Sissel Helm-Petersen, Elena Manuela Teodorescu, Birgitte Preiss, Niels Abildgaard, Peter Gimsing, Danish Myeloma Study Group
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0188988 (2017)
Immunoparesis (hypogammaglobulinemia) is associated to an unfavorable prognosis in newly diagnosed Multiple myeloma (MM) patients. However, this finding has not been validated in an unselected population-based cohort. We analyzed 2558 newly diagnosed
Externí odkaz:
https://doaj.org/article/90e93f8499044324a516c91c6c015912
Autor:
Agoston Gyula Szabo, Robert Schou Pedersen, Henrik Gregersen, Louise Redder, Carsten Helleberg, P Gimsing, Ulf Christian Frølund, Per Trøllund Pedersen, Mikael Frederiksen, Tobias Wirenfeldt Klausen, Annette Juul Vangsted, Morten Salomo, Niels Frost Andersen, Niels Abildgaard, Lene Kongsgaard Nielsen, Henrik Frederiksen
Publikováno v:
Redder, L, Klausen, T W, Vangsted, A J, Gregersen, H, Andersen, N F, Pedersen, R S, Szabo, A G, Frederiksen, M, Frølund, U C, Helleberg, C, Nielsen, L K, Pedersen, P T, Salomo, M, Gimsing, P, Frederiksen, H & Abildgaard, N 2021, ' Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry ', British Journal of Haematology, vol. 193, no. 1, pp. 119-124 . https://doi.org/10.1111/bjh.16806
Redder, L, Klausen, T W, Vangsted, A J, Gregersen, H, Andersen, N F, Pedersen, R S, Szabo, A G, Frederiksen, M, Frølund, U C, Helleberg, C, Nielsen, L K, Pedersen, P T, Salomo, M, Gimsing, P, Frederiksen, H & Abildgaard, N 2021, ' Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation : a population-based study from the Danish national multiple myeloma registry ', British Journal of Haematology, vol. 193, no. 1, pp. 119-124 . https://doi.org/10.1111/bjh.16806
Redder, L, Klausen, T W, Vangsted, A J, Gregersen, H, Andersen, N F, Pedersen, R S, Szabo, A G, Frederiksen, M, Frolund, U C, Helleberg, C, Nielsen, L K, Pedersen, P T, Salomo, M, Gimsing, P, Frederiksen, H & Abildgaard, N 2020, ' Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry ', British Journal of Haematology . https://doi.org/10.1111/bjh.16806
Redder, L, Klausen, T W, Vangsted, A J, Gregersen, H, Andersen, N F, Pedersen, R S, Szabo, A G, Frederiksen, M, Frølund, U C, Helleberg, C, Nielsen, L K, Pedersen, P T, Salomo, M, Gimsing, P, Frederiksen, H & Abildgaard, N 2021, ' Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation : a population-based study from the Danish national multiple myeloma registry ', British Journal of Haematology, vol. 193, no. 1, pp. 119-124 . https://doi.org/10.1111/bjh.16806
Redder, L, Klausen, T W, Vangsted, A J, Gregersen, H, Andersen, N F, Pedersen, R S, Szabo, A G, Frederiksen, M, Frolund, U C, Helleberg, C, Nielsen, L K, Pedersen, P T, Salomo, M, Gimsing, P, Frederiksen, H & Abildgaard, N 2020, ' Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry ', British Journal of Haematology . https://doi.org/10.1111/bjh.16806
In 2019 the UK Myeloma Research Alliance introduced the Myeloma Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible for autologous stem cell transplantation. To validate the MRP in a populat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::420d0d3c518ae1422ff654a91cb0348a
https://vbn.aau.dk/da/publications/aa9f3e41-576c-4296-92c3-140001af08a4
https://vbn.aau.dk/da/publications/aa9f3e41-576c-4296-92c3-140001af08a4
Autor:
Jacob Crafoord, Nina Gulbrandsen, Per Axelsson, Anders Waage, Ulf Christian Frølund, Carsten Helleberg, Olga Stromberg, Galina Tsykunova, Kari Remes, Cecilie Blimark, Niels Frost Andersen, Niels Abildgaard, Markus Hansson, Henrik Eshøj, Kristina Carlson, Tobias Wirenfeldt Klausen, Annette Juul Vangsted, Valdas Peceliunas, Fredrik Schjesvold, Henrik Gregersen, Hareth Nahi
Publikováno v:
Gregersen, H, Peceliunas, V, Remes, K, Schjesvold, F, Abildgaard, N, Nahi, H, Andersen, N F, Vangsted, A J, Klausen, T W, Helleberg, C, Carlson, K, Frølund, U C, Axelsson, P, Stromberg, O, Blimark, C H, Crafoord, J, Tsykunova, G, Eshoj, H R, Waage, A, Hansson, M & Gulbrandsen, N 2022, ' Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group ', European journal of haematology, vol. 108, no. 1, pp. 34-44 . https://doi.org/10.1111/ejh.13709
Gregersen, H, Peceliunas, V, Remes, K, Schjesvold, F, Abildgaard, N, Nahi, H, Andersen, N F, Vangsted, A J, Klausen, T W, Helleberg, C, Carlson, K, Frølund, U C, Axelsson, P, Stromberg, O, Blimark, C H, Crafoord, J, Tsykunova, G, Eshoj, H R, Waage, A, Hansson, M & Gulbrandsen, N 2022, ' Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group ', European Journal of Haematology, vol. 108, no. 1, pp. 34-44 . https://doi.org/10.1111/ejh.13709
European Journal of Haematology
Gregersen, H, Peceliunas, V, Remes, K, Schjesvold, F, Abildgaard, N, Nahi, H, Andersen, N F, Vangsted, A J, Klausen, T W, Helleberg, C, Carlson, K, Frølund, U C, Axelsson, P, Stromberg, O, Blimark, C H, Crafoord, J, Tsykunova, G, Eshoj, H R, Waage, A, Hansson, M & Gulbrandsen, N 2022, ' Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group ', European Journal of Haematology, vol. 108, no. 1, pp. 34-44 . https://doi.org/10.1111/ejh.13709
European Journal of Haematology
OBJECTIVE: We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::540ceb7a1f486cc7fc6778a05c6571f5
http://hdl.handle.net/10852/92181
http://hdl.handle.net/10852/92181